Table 2.
Summary of the clinical trials using PCR2 therapy in cancer.
| Subgroup | Compound | Clinical Trial | Phase | Clinical Trial Identifier | Status |
|---|---|---|---|---|---|
| EZH2 inhibitors |
Tazemetostat | Patients with relapsed, refractory follicular lymphoma | III | NCT04224493 | Recruiting |
| In combination with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma | I/II | NCT03854474 | Recruiting | ||
| Patients with moderate and severe hepatic impairment with advanced malignancies | I | NCT04241835 | Recruiting | ||
| Patients with refractory B-cell non-Hodgkin’s lymphoma with EZH2 gene mutation | II | NCT03456726 | Active | ||
| Patients with recurrent ovarian or endometrial cancer | II | NCT03348631 | Suspended | ||
| Patients with B-cell lymphoma or advance solid tumors | I | NCT03010982 | Completed | ||
| Patients with mCRPC (+abiraterone/prednisone or enzalutamide) | II | NCT02875548 | Ongoing | ||
| Patients with advanced epithelioid sarcoma in combination with doxorubicin | III | NCT04204841 | Recruiting | ||
| Prelapsed or refractory INI-1 negative tumors or synovial sarcoma, rhabdoid tumors, malignant rhabdoid tumors of ovary | I | NCT02601937 | Recruiting | ||
| In combination with Atezolizumab and Obinutuzumab in relapsed/refractory follicular Lymphoma and diffuse Large B-cell Lymphoma | I | NTC02220842 | Completed | ||
| In combination with doxorubicin and HCI for advanced soft-tissue sarcoma or epitheloid sarcoma | III | NCT04204941 | Recruiting | ||
| CPI-1205 | ProSTAT: Patients with mCRPC in combination with abiraterone/prednisone (ARPI) | II | NCT03480646 | Recruiting | |
| ORIO-E: Patients with advanced solid tumors in combination with ipilimumab | I/II | NCT03525795 | Recruiting | ||
| Patients with B-cell lymphomas | I | NCT02395601 | Completed | ||
| Hepatic impairment advanced malignant solid tumor | I | NCT04241835 | Recruiting | ||
| CPI-0209 | Patients with advanced solid tumors in combination with irinotecam | I/II | NCT04104776 | Recruiting | |
| Valemetostat | Patients with acute myelogenous leukemia or acute lymphocytic leukaemia | I/II | NCT03110354 | Completed | |
| Patients with recurrent SCLC in combination with irinotecam | I/II | NCT03879798 | Recruiting | ||
| Patients with non-Hodgkin lymphoma (NHL) | I | NCT02732275 | Active | ||
| Patients with relapsed/refractory adult T-cell leukaemia or lymphoma | II | NCT04102150 | Active | ||
| Participants with hepatic impairments (single-dose) | I | NCT04276662 | Completed | ||
| PF-06821497 | Patients with follicular lymphoma, CRPC and relapsed/refractory small cell lung cancer (SCLC) | I | NCT03460977 | Recruiting | |
| SHR2554 | Relapsed or refractory mature lymphoid neoplams | I | NCT03741712 | Recruiting | |
| SHR2554 | In combination with SHR3680 (inhibits androgen-mediated translocation of AR) in CRPC | I/II | NCT03460977 | Recruiting | |
| EPZ-6438+ARPI | CELLO-1: Patients with mCRPC who have not received chemotherapy | I/II | NCT04179864 | Recruiting | |
| Dual EZH2 inhibitors | DS-3201b | Patients with hepatic impairment (single dose DS-3201b) | I | NCT04276662 | Recruiting |
| Patients with adult T-cell leukemia/lymphoma | II | NCT04102150 | Recruiting | ||
| Patients with SCLC with irinotecam | I/II | NCT3879798 | Recruiting | ||
| Patients with lymphomas | I | NCT02732275 | Recruiting | ||
| EED inhibitors | MAK683 | Patients with advanced malignancies (diffuse large B cell lymphoma) | I/II | NCT02900561 | Recruiting |